SEC Form 4 · accession 0001209191-16-122854
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Debora Jorn
Director
Period of report
May 20, 2016
Accepted (ET)
May 24, 2016 · 2:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $0.40 | May 20, 2016 | A | 70,000 | A | — | May 19, 2026 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F11/36th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 5/20/2016, so that all of the shares of the stock subject to the option shall be vested on 5/20/2019, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date.
- F2Not Applicable